State NC
Clinical Trials in North Carolina
Recruiting clinical trials with at least one study location in North Carolina. Data updated daily from ClinicalTrials.gov.
Top Conditions in North Carolina
Frequently Asked Questions — Clinical Trials in North Carolina
How many clinical trials are currently recruiting in North Carolina?
ClinicalMetric currently tracks 396 actively recruiting clinical trials with at least one location in North Carolina. The total number of registered studies—including active but not currently enrolling trials—is 396. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in North Carolina?
North Carolina hosts clinical trials across a broad range of medical conditions, including Breast Cancer, Multiple Myeloma, Cancer, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout North Carolina serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in North Carolina?
To join a clinical trial in North Carolina, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in North Carolina maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in North Carolina
NCT07015697 Phase 1
Recruiting
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic S...
Condition
Recurrent or Metastatic Solid Tumors
Enrollment
76 pts
Location
United States, France, Japan
Sponsor
Daiichi Sankyo
NCT07225686 Phase 3
Recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sl...
Condition
Obesity
Enrollment
250 pts
Location
United States, Australia, Brazil
Sponsor
Amgen
NCT07222670 Phase 2
Recruiting
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing R...
Condition
Viral Respiratory Infection
Enrollment
1,100 pts
Location
United States
Sponsor
ENA Respiratory Pty Ltd
NCT05238922 Phase 1
Recruiting
Study of INCB123667 in Subjects With Advanced Solid Tumors
Condition
Solid Tumors
Enrollment
604 pts
Location
United States, France, Italy
Sponsor
Incyte Corporation
NCT07225127 N/A
Recruiting
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder ...
Condition
Bladder Cancer
Enrollment
408 pts
Location
United States
Sponsor
University of Washington
NCT05580562 Phase 3
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study...
Condition
H3 K27M
Enrollment
510 pts
Location
United States, Argentina, Australia
Sponsor
Jazz Pharmaceuticals
NCT06174103 N/A
Recruiting
BiVACOR® Total Artificial Heart Early Feasibility Study
Condition
Heart Failure
Enrollment
5 pts
Location
United States
Sponsor
BiVACOR Inc.
NCT04879329 Phase 2
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Th...
Condition
Urothelial Carcinoma
Enrollment
372 pts
Location
United States, Argentina, Australia
Sponsor
Seagen, a wholly owned subsidi
NCT02852031 N/A
Recruiting
National Collaborative to Improve Care of Children With Complex Congenital Heart...
Condition
Hypoplastic Left Heart Syndrome (HLHS)
Enrollment
1,000 pts
Location
United States, Canada, United Kingdom
Sponsor
Children's Hospital Medical Ce
NCT07444268 Phase 1
Recruiting
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a S...
Condition
Advanced Hematologic Malignancies
Enrollment
8 pts
Location
United States
Sponsor
Sumitomo Pharma America, Inc.
NCT07052942 Phase 4
Recruiting
Individualizing Treatment for Asthma in Primary Care (Full Study)
Condition
Asthma
Enrollment
3,200 pts
Location
United States
Sponsor
DARTNet Institute
NCT07534254 N/A
Recruiting
Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Pr...
Condition
Overweight and/or Obesity
Enrollment
20 pts
Location
United States
Sponsor
University of North Carolina,
NCT06995677 Phase 2
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, In...
Condition
Low-grade NMIBC
Enrollment
90 pts
Location
United States, Australia, Italy
Sponsor
Tyra Biosciences, Inc
NCT04239573 N/A
Recruiting
Comparing Two Methods to Follow Patients With Pancreatic Cysts
Condition
Pancreatic Carcinoma
Enrollment
4,606 pts
Location
United States, Canada, Puerto Rico
Sponsor
ECOG-ACRIN Cancer Research Gro
NCT05212272 N/A
Recruiting
MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Condition
High Grade Glioma
Enrollment
16 pts
Location
United States
Sponsor
Wake Forest University Health
NCT06266689 N/A
Recruiting
Project humAn dieTary daTa rEtuRN
Condition
Diet Habit
Enrollment
600 pts
Location
United States
Sponsor
Duke University
NCT07216261 N/A
Recruiting
Implementing Cognitive Behavioral Therapy for Insomnia (SWELL): Function QUERI 3...
Condition
Chronic Insomnia
Enrollment
20 pts
Location
United States
Sponsor
VA Office of Research and Deve
NCT07215624 N/A
Recruiting
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Netw...
Condition
Malignant Digestive System Neoplasm
Enrollment
500 pts
Location
United States, Puerto Rico
Sponsor
Wake Forest University Health
NCT06701682 Phase 2
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilob...
Condition
Acute Respiratory Distress Syndrome (ARDS)
Enrollment
200 pts
Location
United States
Sponsor
PPD Development, LP
NCT06926868 Phase 2, Phase 3
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Prev...
Condition
Breast Neoplasms
Enrollment
500 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT05555589 Phase 3
Recruiting
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for th...
Condition
Neurotrophic Keratopathy
Enrollment
70 pts
Location
United States, Italy, Poland
Sponsor
ReGenTree, LLC
NCT04647227 Phase 4
Recruiting
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Condition
Hemophilia A With Inhibitor
Enrollment
55 pts
Location
United States
Sponsor
American Thrombosis and Hemost
NCT07142356 Phase 2
Recruiting
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Condition
Uncontrolled Hypertension
Enrollment
280 pts
Location
United States
Sponsor
Retension Pharmaceuticals. Inc
NCT05096481 Phase 2
Recruiting
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and...
Condition
High Grade Glioma
Enrollment
120 pts
Location
United States
Sponsor
Nationwide Children's Hospital
NCT05303519 Phase 3
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Condition
Glioma
Enrollment
365 pts
Location
United States, Australia, China
Sponsor
Nuvation Bio Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology